Kuria Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kuria Therapeutics, Inc. - overview
Established
2022
Location
Little Rock, AR, US
Primary Industry
Healthcare Specialists
About
Based in Arkansas, US, and founded in 2022, Kuria Therapeutics, Inc. operates as a developer of healthcare solutions for the treatment of eye and skin-related issues. In September 2022, Kuria Therapeutics, Inc. , led by its CEO Keith W.
Ward, raised series A funding. The company's product portfolio includes KTX-1161 which is a topical ophthalmic formulation of SCO-116 (a novel Nrf2 activator). This product is focused on the corneal endothelium, a single layer of cells responsible for corneal transparency and vision. The other products under the developing stage include KTX-1162 and KTX-1163.
The company intends to use the funds raised in September 2022 to support the lead ophthalmic formulation, preclinical studies, and manufacturing activities IND-enabling for clinical studies.
Primary Industry
Healthcare Specialists
Sub Industries
Optometrists & Opticians Products and Services
Website
www.kuriatx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Kuria Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.